Skip to main content


Details of the Drug
Generic Name:
nye vol' ue mab
Drug Type:
Monoclonal antibody
How the Drug is Given:
Intravenously (IV)

Indications and Usage

​Nivolumab is FDA approved for the treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and posttransplantation brentuximab vedotin. 

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Side effects needing medical attention

Fatigue, upper respiratory tract infection, fever, diarrhea, and cough.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.